Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | ACP3 | P15309 | 2/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535283 | 1.00 | PNMT (0.61) | PNMTCES2ACP3PTPN5DAO | |
| SCHEMBL343403 | 1.00 | PNMT (0.61) | PNMTCES2ACP3PTPN5DAO | |
| SCHEMBL29404730 | 1.00 | PNMT (0.61) | PNMTCES2ACP3PTPN5DAO | |
| SCHEMBL26036716 | 0.86 | PTPN5 (0.48) | PNMTCES2ACP3PTPN5DAO | |
| SCHEMBL29755658 | 0.86 | PTPN5 (0.48) | PNMTCES2ACP3PTPN5DAO | |
| SCHEMBL30365820 | 0.85 | PNMT (0.57) | PNMTCES2ACP3DAOPDE2A | |
| SCHEMBL28620855 | 0.85 | PNMT (0.57) | PNMTCES2ACP3DAOPDE2A | |
| SCHEMBL4135956 | 0.83 | PNMT (0.65) | PNMTCES2ACP3DAOIDO1 | |
| SCHEMBL255035 | 0.83 | PNMT (0.55) | PNMTCES2ACP3PTPN5DAO | |
| SCHEMBL2601113 | 0.83 | DAO (0.59) | PNMTCES2ACP3DAOIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115976007-A | Nanometer double enzyme conjugate and application thereof in synthesis of (S) -1- (3-trifluoromethyl phenyl) ethanol | 浙江工业大学 | 2023-04-18 | — | — | CN | claimed |
| CN-112176019-A | Method for preparing (R) -1- (3-trifluoromethylphenyl) ethanol by biological catalysis | 浙江工业大学 | 2021-01-05 | — | — | CN | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| CN-116102430-B | Alkylation synthesis method for in-situ catalytic alcohols | 中山大学 | 2025-03-14 | — | — | CN | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4219493-A1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116144617-A | NADH dependent alcohol dehydrogenase CpSADH, coding gene, strain and application | 浙江工业大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-116121216-A | Fusion enzyme of carbonyl reductase and glucose dehydrogenase, coding gene, engineering bacteria and application | 浙江工业大学 | 2023-05-16 | — | — | CN | disclosed |
| CN-116102430-A | Alkylation synthesis method for in-situ catalytic alcohols | 中山大学 | 2023-05-12 | — | — | CN | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| CN-1069882-A | The Compounds and methods for that suppresses HIV and correlated virus | MEDIVIR AB (CH) | 1993-03-17 | — | — | CN | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
| US-4554111-A | α-Hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-11-19 | — | — | US | disclosed |
| US-4544652-A | α-Hydroxyethylphosphinates, and their use as fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-10-01 | — | — | US | disclosed |
| EP-0093010-A2 | Alpha-hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-11-02 | — | — | EP | disclosed |
| US-4185992-A | Imidazole derivatives | MAY & BAKER LIMITED (GB) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | PNMT 2574/4885CES2 790/4885ACP3 105/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | PNMT 2574/4885CES2 790/4885ACP3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.